Total number of AIM Companies (Incl Susp):
Total number of AIM Companies trading:
*as at close of business 14 October 2019
Standard List** of Main Market:
Total number of Standard List Companies
Total number of Standard List Companies trading:
*as at close of business 14 October 2019
NEX Growth Market:
Total number of NEX Growth Market Companies (Incl Susp):
Total number of NEX Growth Market Companies trading:
*as at close of business 14 October 2019
*A corporate client of Hybridan LLP
** Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity
Dish of the day
No Joiners Today
Off the menu
No Leavers Today
What’s cooking in the IPO kitchen?
Main Market premium
Registration document approved for Helios Towers. The Group provides essential network services, flexible infrastructure solutions and reliable power supply to mobile network operators in five African growth economies. Revenue increased 7 per cent. year-on-year to US$191m (H1 2018: US$178m), with Adjusted EBITDA up 15 per cent. year-on-year at US$99m (H1 2018: US$86m) for the six months ended 30 June 2019. Pricing rumoured at 115p to 145p implying valuation of up to $1.8bn. Expected 18 Oct 2019.
African Export-Import Bank a supranational financial institution whose purpose is to facilitate, promote and expand intra- and extra- African trade, of its potential intention to publish a registration document, the Bank hereby confirms its intention to proceed with an Initial Public Offering. The GDRs are expected to be admitted to the standard listing segment of the Official List of the FCA and to trading on the Main Market of the LSE.
Sareum Holdings* (LON:SAR) 0.33p £9.67m
The specialist small molecule drug development business, announced that, further to its announcement of 27 September 2019, the abstract for the poster that the Company will present at the American Association for Cancer Research (AACR) National Cancer Institute (NCI) European Organisation for Research and Treatment of Cancer (EORTC) International Conference, has now been published on the conference website. Dr Tim Mitchell, will present the poster on 29 October 2019. The preclinical data demonstrates "a significant reduction of tumour growth in preclinical models of many cancer types via a novel immunotherapeutic mechanism of action. These data suggest that our TYK2/JAK1 inhibitor could also offer the additional potential advantage of oral delivery. This contrasts with currently marketed cancer immunotherapies, which can only be dosed by injection. “
Tatton Asset Mgt (LON:TAM) 210p £117m
Tatton Asset Management, the on-platform discretionary fund management (DFM) and IFA support services business, is today providing an unaudited period end update for the 6 months ended 30 September 2019.
The Group continued to perform well during the period and the progress outlined at the year-end results reported on 3 June 2019 has continued.
Tatton Investment Management continues to grow strongly. Assets under management (AUM) increased to £7.0 billion at 30 September 2019 (31 March 2019: £6.1 billion) which includes £135m of AUM from the Sinfonia acquisition completed recently and announced today. This is an increase of £0.9 billion or 14.8% for the six-month period. Organic growth of AUM was 12.5%.
Net inflows for the six months to September 2019 were £441m, an increase of 7.2% of AUM.
Pantheon Resources (LON:PANR) 17p £85.5m
Pantheon Resources, the AIM-quoted oil and gas exploration company with working interests in several conventional project areas in Tyler and Polk Counties, onshore East Texas, and onshore North Slope of Alaska, is pleased to provide shareholders with the following update:
Increased ownership in Alkaid/Phecda (Alaska) from 75% to 100%
Pantheon reports that it has executed a contractual agreement with Halliburton to acquire its 25% working interest in the six leases jointly held with Pantheon on the North Slope of Alaska. Under the agreement, which is subject to a customary approval process by the State of Alaska Department of Natural Resources, Halliburton will transfer to Pantheon their entire working interests in the leases in exchange for Pantheon accepting full responsibility for all future lease obligations.
Creo Medical Group (LON:CREO) 173.5p £211m
The medical device company focused on the emerging field of surgical endoscopy, announces that Queen Elizabeth The Queen Mother Hospital in Margate, part of the East Kent Hospitals University NHS Foundation Trust, today hosts its third endoscopy training course. The three-day training course will include live demonstrations and hands-on stations training on Creo's Speedboat device
The Course convenor is Dr Zacharias Tsiamoulos, Consultant in Gastroenterology and Specialist in GI Endoscopy at the East Kent Trust. Dr Tsiamoulos is a key opinion leader in the field of Gastrointestinal therapeutic endoscopy and a leading user of Speedboat for colorectal endoscopic submucosal dissection, an advanced surgical procedure using endoscopy to remove gastrointestinal pre-cancerous lesions that have not entered the muscle layer.
IG Design Group (LON:IGR) 619p £482m
IG Design Group, one of the world's leading designers, innovators and manufacturers of gift packaging, greetings, stationery, creative play products and giftware, announces a trading update for the first half of the financial year, which covers the six month period to 30 September 2019.
The Group is pleased to report a strong performance over the period; on track to meet full year market expectations, with the business delivering double digit year on year growth in revenue and operating profit. The Group continues to deliver strong cash generation and as a result we expect year end average leverage1 to show further improvement against the prior year, reaching around 1.1x.
Agronomics Limited (LON:ANIC) 5.85p £6.66m
The Board of announced it has completed a subscription of US$ 1,500,000 in VitroLabs Inc. VitroLabs, headquartered in San Jose, USA, is developing laboratory-produced, cruelty-free leather. The Subscription is in the form of a SAFE, that will convert at VitroLabs' next funding round giving Agronomics an expected interest of approximately 3.79% in the form of Series A Standard Preferred Stock. The Subscription will be paid using cash from the Company's own resources.
Renalytix AI (LON:RENX) 253p £149m
Renalytix AI, a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that Capital District Physicians' Health Plan, Inc. (CDPHP®), a physician led health insurance provider, has adopted coverage determination policies that will provide KidneyIntelX™ for qualified CDPHP members who have Type 2 diabetes and chronic kidney disease (diabetic kidney disease or "DKD"). In the United States, approximately 12m people currently have diabetic kidney disease1. Qualified CDPHP members are eligible for KidneyIntelX™ testing and score reporting for the risk of rapid progression of kidney disease.
Alpha FX Group (LON:AFX) 895p £315m
Alpha, a foreign exchange and payments specialist working for corporates and institutions internationally, today announces a trading update for the year ending 31 December 2019.
The Board announced that trading has continued to be strong. Growth continues to be derived from the core UK corporate market, European clients serviced from the London office, as well as the Institutional division and the broadening of the product base into currency options. The newly launched operations in Canada and Alpha Pay also continue to make positive revenue contributions to the Group.
As a result of the strong performance , the Board expects earnings for the year ending 31 December 2019 to be ahead of current market expectations.
Feedback (LON:FDBK) 1.40p £6.5m
Feedback, the specialist medical imaging technology company, provides an update on Bleepa®.
The Company is considering a number of potential opportunities for Bleepa® following its launch at the NHS Expo in September 2019. The Company is in advanced discussions with NHS pilot sites whilst additionally pursuing a number of commercial opportunities within and outside the NHS, and hopes to commence Bleepa® pilot schemes in the near future.
Harvest Minerals (LON:HMI) 4.4p £8.2m
Harvest Minerals Limited, the AIM quoted remineraliser producer, announces that following publication of its audited financial statements for the year ended 30 June 2019, it will change its financial year end from 30 June to 31 December.
Rationale for Change is the Company's production and sales cycles work predominately on a calendar basis, consistent with the planting seasons in the Southern Hemisphere, however, its existing financial accounting period has a 30 June year end, which is typical of most Australian incorporated companies.
0203 764 2344
0203 764 2342